CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
LipoMedix is developing Promitil®, a novel nanomedicine for enhancing the effectiveness of chemo-radiotherapy in cancer treatment. This liposome formulation improves the delivery and activation of the anti-cancer agent Mitomycin-C, aiming to provide a safer and more effective treatment option for patients.
There were over 18M new cases of cancer worldwide in 2018, out of which about 3.7M were in Europe.
To treat cancer, radiotherapy is increasingly used in combination with chemotherapy.
Chemo-radiotherapy is a non-invasive approach for cancer local control, given within a reduced period time and with potential for complete cure of cancer.
The key to enabling the full potential of chemo-radiotherapy depends on radio-sensitization, which means the degree of effectiveness of the anti-cancer agents us…
LIPOMEDIX PHARMACEUTICALS LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
